BitNile Holdings Announces That Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Clinical Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Alzheimer’s Disease
Information presented herein is for discussion purposes only and is not a recommendation or an offer or solicitation to buy or sell any securities. Securities identified do not represent all of the securities purchased, sold, or recommended to advisory clients of the speaker. the views and opinions expressed by the speaker are his own as of the date of the recording. Any such views are subject to change at any time based upon market or other conditions and we disclaim any responsibility to update such views. These views should not be relied on as investment advice and may not be relied on as an indication of trading intent. Neither the speaker nor we can be held responsible for any direct or incidental loss incurred by using any of the information provided hereby.